NCT01137110

Short Duration Levetiracetam to Extended Course for Seizure Prophylaxis After aSAH

Comparison of Short Duration Levetiracetam to Extended Course Levetiracetam for Seizure Prophylaxis Following Subarachnoid Hemorrhage

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 84 (actual)
• Sponsor: Washington University School of Medicine · Academic / Other
• Sex: All
• Age: 18 Years – 99 Years
• Healthy volunteers: Not accepted

Summary

Our primary objective is to compare two treatment options for prevention of seizures following a subarachnoid hemorrhage and determine if a short-course regimen of levetiracetam is as efficacious in the prevention of in-hospital seizures when compared to an extended course.

Detailed description

This is a prospective, single-center, randomized, controlled trial. Patients admitted with spontaneous SAH (and meet enrollment criteria) will be randomized to either levetiracetam 1000 mg twice daily for 3 days or levetiracetam 1000mg twice daily until hospital discharge.

Conditions

• Subarachnoid Hemorrhage

Interventions

Type	Name	Description
OTHER	Brief LEV	Levetiracetam 1000mg BID x 3 days for prophylaxis
OTHER	Extended LEV	Levetiracetam 1000mg BID for length of hospital stay for prophylaxis

Timeline

• Start date: 2010-05-01
• Primary completion: 2013-01-01
• Completion: 2017-01-01
• First posted: 2010-06-04
• Last updated: 2019-07-12
• Results posted: 2019-07-12

Locations

1 site across 1 country: United States